Drugs / ATG
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03121001 Background | Mar 2017 → May 2029 expected | sickle cell disease | University of Illinois at Chicago | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03121001 ↗ |
| Route | Intravenous | “0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7” NCT03121001 ↗ |